Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI), a medical technology company, announced the appointment of Michelle Brennan as interim Chief Executive Officer, effective September 24, 2024. The announcement was made through an 8-K filing with the Securities and Exchange Commission on Monday, reflecting the company's recent executive changes.
Brennan, who joined the Masimo Board of Directors in 2023, brings over three decades of experience from her tenure at Johnson & Johnson, where she led medical device and consumer pharmaceutical businesses. Her appointment as interim CEO is set for a term of six months, with the potential for an earlier termination as per the agreement terms.
Under the employment agreement, Brennan will receive an annual base salary of $1,042,000 and is eligible for a discretionary bonus with a target of $621,250, to be determined by the Board at the term's end. Additionally, she has been granted 8,916 restricted stock units (RSUs), which will vest on March 24, 2025, or upon the appointment of a new CEO, whichever occurs first.
The RSUs are part of the company's 2017 Equity Incentive Plan and are consistent with grants provided to other Masimo employees.
Brennan's compensation package aligns her with other senior executives, granting her access to the company's employee benefits plans and programs.
The information for this article is based on a press release statement from the SEC filing.
In other recent news, Masimo Corporation reported robust growth in its third quarter of 2024, with a year-over-year increase in healthcare revenues and a solid non-GAAP earnings per share growth. The company projected positive figures for the fourth quarter and full year 2024, despite a decline in non-healthcare revenues and ongoing litigation with Apple (NASDAQ:AAPL).
The healthcare segment saw significant gains, with revenues increasing by 12% year-over-year to $343 million, while non-GAAP earnings per share grew by 31% to $0.98. The company also revealed strategic plans for long-term growth and margin improvements.
Masimo Corporation is exploring strategic alternatives for its consumer business and aims to double earnings per share within five years. The company also plans to improve operating margins by 200 basis points by 2025.
These recent developments indicate a strong market position for Masimo, with unrecognized contract revenues reaching $1.65 billion. The company is also expanding its board to eight directors and is in the process of searching for a permanent CEO.
Despite some challenges in the non-healthcare sector, Masimo's healthcare division is thriving, and its long-term outlook remains positive.
InvestingPro Insights
As Masimo Corporation (NASDAQ:MASI) transitions to new leadership under Michelle Brennan, investors may find value in examining the company's current financial position. According to InvestingPro data, Masimo boasts a market capitalization of $8.62 billion, reflecting its significant presence in the medical technology sector. The company's revenue for the last twelve months stands at $2.04 billion, with a gross profit margin of 50.05%, indicating a strong ability to generate profit from its core business operations.
InvestingPro Tips highlight that Masimo is expected to see net income growth this year, which could be a positive sign for the company's financial health under new leadership. Additionally, the company operates with a moderate level of debt, potentially providing financial flexibility as it navigates this transition period.
However, investors should note that Masimo is trading at a high P/E ratio of 109.33, suggesting the stock may be priced at a premium compared to its earnings. This valuation metric, along with the fact that Masimo is trading near its 52-week high, may be important considerations for investors evaluating the stock's current price levels.
For those seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide deeper insights into Masimo's financial outlook and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.